Discover 764 paid clinical trials in Washington, D.C.. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 764
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Location: Washington D.C. DC, Hanover PA, Gettysburg PA, York PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04181060
Phase3, Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
for
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Location: Washington D.C. DC, Kensington MD, McLean VA, Largo MD,
Sponsor: NRG Oncology
Sex: All
Age: 45 - 70
Code: NCT05080673
Recruiting
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
for
Metastatic Malignant Neoplasm in the Liver,
Location: Washington D.C. DC, Baltimore MD, Richmond VA,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05040360
Phase2, Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Washington D.C. DC, Glen Burnie MD, Baltimore MD,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06058377
Phase3, Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
for
Locally Advanced Head and Neck Squamous Cell Carcinoma
Location: Washington D.C. DC, Bethesda MD, Hyattsville MD,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT06129864
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
for
Viral Lung Infection and Acute Respiratory Failure
Location: Washington D.C. DC, Annapolis MD, Charlottesville VA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05624450
Phase3, Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
for
Chronic Kidney Disease and Hypertension
Location: Washington D.C. DC, Arlington VA, Bethesda MD,
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
for
Fabry Disease, Pregnancy, Pregnancy Complications
Location: Washington D.C. DC
Sponsor: Chiesi Farmaceutici S.p.A.
Sex: Female
Age: 0+
Code: NCT06941025
Recruiting
Stress, Sleep and Cardiovascular Risk
for
Posttraumatic Stress Disorder, Insomnia
Location: Washington DC
Sponsor: Howard University
Sex: All
Age: 18 - 35
Code: NCT03487991
Recruiting
BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis
for
Violence Risk, Early Psychosis
Location: Washington D.C. DC
Sponsor: Howard University
Sex: All
Age: 16 - 30
Code: NCT07417904
Recruiting
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
for
Chronic Spontaneous Urticaria (CSU)
Location: Washington D.C. DC, Chevy Chase MD, Vienna VA,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06868212
Phase3, Recruiting
Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates
for
Osteoporosis
Location: Washington DC
Sponsor: National Bone Health Alliance
Sex: All
Age: 50+
Code: NCT02575157
Recruiting
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
for
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors,
Location: Washington D.C. DC, Durham NC, Cincinnati OH,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 1 - 70+
Code: NCT05868629
Recruiting
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
for
Relapsed/Refractory Primary Central Nervous System Lymphoma
Location: Washington D.C. DC, Baltimore MD, Hershey PA,